BR112022005757A2 - Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma - Google Patents

Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma

Info

Publication number
BR112022005757A2
BR112022005757A2 BR112022005757A BR112022005757A BR112022005757A2 BR 112022005757 A2 BR112022005757 A2 BR 112022005757A2 BR 112022005757 A BR112022005757 A BR 112022005757A BR 112022005757 A BR112022005757 A BR 112022005757A BR 112022005757 A2 BR112022005757 A2 BR 112022005757A2
Authority
BR
Brazil
Prior art keywords
same
uricase
treatment method
improved
improved uricase
Prior art date
Application number
BR112022005757A
Other languages
English (en)
Inventor
Guofeng Huang
Hongchuan Liu
Jing Zhang
Peng Zhao
Ruisheng Li
Sheng Yao
Si Chen
Tie Li
Yuehua Zhou
Original Assignee
Shanghai Junshi Biosciences Co Ltd
Suzhou Junmeng Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Junshi Biosciences Co Ltd, Suzhou Junmeng Biosciences Co Ltd filed Critical Shanghai Junshi Biosciences Co Ltd
Publication of BR112022005757A2 publication Critical patent/BR112022005757A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12N9/0048—Uricase (1.7.3.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma. a presente invenção refere-se a uma uricase aperfeiçoada, um método de tratamento de hiperuricemia usando a mesma, e uma composição farmacêutica compreendendo a uricase. a uricase aperfeiçoada compreende uma sequência de aminoácidos que apresenta pelo menos cerca de 90% de identidade com id seq nº: 1, em que a sequência não é id seq nº: 1.
BR112022005757A 2019-10-11 2020-10-10 Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma BR112022005757A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910964325.4A CN112646790A (zh) 2019-10-11 2019-10-11 改进的尿酸酶及其用于治疗高尿酸血症的方法
PCT/CN2020/120133 WO2021068925A1 (zh) 2019-10-11 2020-10-10 改进的尿酸酶及其用于治疗高尿酸血症的方法

Publications (1)

Publication Number Publication Date
BR112022005757A2 true BR112022005757A2 (pt) 2022-06-21

Family

ID=75342725

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005757A BR112022005757A2 (pt) 2019-10-11 2020-10-10 Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma

Country Status (9)

Country Link
US (1) US20230073183A1 (pt)
EP (1) EP4043559A1 (pt)
JP (1) JP2022553648A (pt)
KR (1) KR20220078647A (pt)
CN (2) CN112646790A (pt)
AU (1) AU2020362820A1 (pt)
BR (1) BR112022005757A2 (pt)
CA (1) CA3153029A1 (pt)
WO (1) WO2021068925A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112646790A (zh) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 改进的尿酸酶及其用于治疗高尿酸血症的方法
CN115197922B (zh) * 2021-04-09 2024-05-14 派格生物医药(苏州)股份有限公司 尿酸酶或其同功异型物及其制备方法
CN115197923A (zh) * 2021-04-09 2022-10-18 上海君实生物医药科技股份有限公司 尿酸酶、其药物组合物及其用途
WO2023064732A1 (en) * 2021-10-15 2023-04-20 Georgia State University Research Foundation, Inc. Delivery of therapeutic recombinant uricase using nanoparticles
CN117230034A (zh) * 2023-10-16 2023-12-15 临沂大学 一种高稳定性哺乳动物尿酸氧化酶突变体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188971A1 (en) * 1998-08-06 2006-08-24 Duke University Urate oxidase
HU229774B1 (en) * 1998-08-06 2014-07-28 Univ Durham Urate oxidase
SI3321359T1 (sl) * 2005-04-11 2021-07-30 Horizon Pharma Rheumatology Llc Variantne oblike urat oksidaze in uporaba le-teh
CN101875922B (zh) * 2009-04-30 2012-02-22 重庆医科大学 一种重组苛求芽孢杆菌胞内尿酸酶及其聚乙二醇修饰与应用
KR101637010B1 (ko) * 2015-04-24 2016-07-07 광주과학기술원 위치 특이적으로 알부민이 연결된 요산 산화효소 및 단백질에 위치 특이적으로 알부민을 연결하는 방법
BR112017024212A2 (pt) * 2015-05-15 2018-07-17 Medimmune Llc sequências de uricases melhoradas e métodos de tratamento
CN106554948B (zh) * 2015-09-29 2019-06-25 上海生物制品研究所有限责任公司 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用
CN105543187B (zh) * 2016-02-18 2020-07-10 重庆医科大学 苛求芽孢杆菌尿酸酶突变体v145a
JP2020530282A (ja) * 2017-07-07 2020-10-22 アレナ ファーマシューティカルズ， インコーポレイテッド 組換えウリカーゼ酵素
CN112646790A (zh) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 改进的尿酸酶及其用于治疗高尿酸血症的方法
CN115197923A (zh) * 2021-04-09 2022-10-18 上海君实生物医药科技股份有限公司 尿酸酶、其药物组合物及其用途

Also Published As

Publication number Publication date
AU2020362820A1 (en) 2022-05-05
CN114502728A (zh) 2022-05-13
JP2022553648A (ja) 2022-12-26
CA3153029A1 (en) 2021-04-15
EP4043559A1 (en) 2022-08-17
CN112646790A (zh) 2021-04-13
WO2021068925A1 (zh) 2021-04-15
KR20220078647A (ko) 2022-06-10
US20230073183A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
BR112022005757A2 (pt) Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
CO2017012454A2 (es) Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia
WO2019045248A3 (ko) 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
BR112022007158A2 (pt) Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
WO2018155813A3 (ko) 엔테로코쿠스 패슘에 대하여 용균력을 가지는 신규한 항균단백질 efal-2
MX2020007384A (es) Metodos para tratar la diabetes, la hepatitis y/o la enfermedad inflamatoria del higado.
MX2019009964A (es) Nuevo bacteriofago de clostridium perfringens clo-pep-2 y uso para inhibir la proliferacion de clostridium perfringens.
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
BR112017010238A2 (pt) composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação de fibroblastos e a deposição aberrante de matriz extracelular
EA202192288A1 (ru) Соединения на основе нейрегулина-4 и способы их применения
EA202190888A1 (ru) Пептид для применения в косметике
MX2020012497A (es) Moduladores de la expresion de apol1.
BR0316523A (pt) Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
BR112022007010A2 (pt) Terapia gênica para doença de alzheimer
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
EA201892322A1 (ru) Способ лечения или предупреждения остеоартрита
BR112022001390A2 (pt) Inibidores de enzima
BR112022012473A2 (pt) Composição de tratamento capilar, e, métodos para tratar cabelo, para melhorar a condição do cabelo e para diminuir o ph do cabelo
BR112021017710A2 (pt) Composto, composição farmacêutica, método de tratamento
BR112021026193A2 (pt) Composições e métodos para tratar ou prevenir infecções oculares com filociclovir
MX2021010552A (es) Nuevo peptido y uso del mismo.
MX2017013480A (es) Composicion farmaceutica para tratar y/o prevenir el cancer.
MX2021001228A (es) Composicion para uso en la prevencion y/o tratamiento de la mucosa genitourinaria.
BR112023025986A2 (pt) Compostos úteis no tratamento ou prevenção de um distúrbio mediado por prmt5